Home/Filings/4/0000950170-25-029262
4//SEC Filing

STEPHENSON BRIAN C 4

Accession 0000950170-25-029262

CIK 0001743881other

Filed

Feb 26, 7:00 PM ET

Accepted

Feb 27, 5:36 PM ET

Size

10.2 KB

Accession

0000950170-25-029262

Insider Transaction Report

Form 4
Period: 2025-02-25
STEPHENSON BRIAN C
Secretary, Treasurer & CFO
Transactions
  • Exercise/Conversion

    Common Stock

    2025-02-25$17.00/sh+8,500$144,500110,964 total
  • Sale

    Common Stock

    2025-02-25$33.18/sh8,400$278,697102,564 total
  • Exercise/Conversion

    Stock Option (right to buy)

    2025-02-258,500440,170 total
    Exercise: $17.00Exp: 2029-06-26Common Stock (8,500 underlying)
  • Sale

    Common Stock

    2025-02-25$34.18/sh100$3,418102,464 total
Footnotes (3)
  • [F1]This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 22, 2024.
  • [F2]Represents the weighted average sale price of the shares sold from $32.63 to $33.53 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
  • [F3]The shares subject to this option vested in 48 equal monthly installments from June 26, 2019 to June 26, 2023.

Documents

1 file

Issuer

BridgeBio Pharma, Inc.

CIK 0001743881

Entity typeother

Related Parties

1
  • filerCIK 0001780030

Filing Metadata

Form type
4
Filed
Feb 26, 7:00 PM ET
Accepted
Feb 27, 5:36 PM ET
Size
10.2 KB